Market Overview:
The global depression treatment therapy market is expected to grow at a CAGR of 5.8% from 2018 to 2030. The growth in the market can be attributed to factors such as the increasing prevalence of depression, rising awareness about depression and its treatment, and technological advancements in the field of depression treatment therapies. The global depression treatment therapy market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into drugs and treatment devices. The drugs segment is further sub-segmented into antidepressants, mood stabilizers, antipsychotics, and others (stimulants). The antidepressant sub-segment accounts for a major share of this market owing to their high usage for treating various types of depressive disorders. On the basis of application, the market is divided into seasonal affective disorder (SAD), major depression disorder (MDD), dysthymia disorder (DD), postpartum Depression Disorder (PPD), atypical Depression Disorder(ADD) psychotic Depression Disorder(PDD)and other psychiatric disorders such as obsessive compulsive disorder (OCD)and generalized anxiety disorder(GAD)). SAD held a dominant share in 2017 owing to its high prevalence rate across different geographies worldwide.
Product Definition:
Depression Treatment Therapy is a form of therapy that is used to treat depression. It can help people to manage their symptoms and improve their mood.
Drugs:
The global drugs, it's usage and growth factor in depression treatment therapy market size was valued at USD 16.7 billion in 2015 and is expected to grow at a CAGR of XX% over the forecast period. The increasing prevalence of major depressive disorder (MDD) globally is one of the key factors driving demand for these products during the forecast period.
Treatment device:
Treatment device and it's usage in depression treatment therapy market is a new emerging trend in the market. The major drivers for this market are increasing prevalence of Depression, rising awareness about depression among people and growing acceptance of various therapies such as Electro Convulsive Therapy (ECT), Deep Brain Stimulation (DBS) etc.
Application Insights:
Major depression held the largest share of over 40.0% in 2017 owing to its high prevalence and a large patient base for treatment. According to WHO, as of 2016 major depression was the second most common cause of disability around the world and the leading cause in developed countries like U.S., Canada, New Zealand and France while it is one of the less common causes in developing countries like India, China, Brazil etc. Thus increasing awareness about Depression is expected to fuel market growth during forecast period especially in low-income economies where major depression is more prevalent than other parts of world such as North America and Europe which has been positively impacting demand for antidepressants globally since past few years due to technological advancements & new product launches by various companies including Pfizer Inc., Eli Lilly & Company; Janssen Pharmaceuticals; Astrazeneca Ltd.; Allergan PLC; Actavis PLC; Forest Laboratories Inc.; Sun Pharmaceutical Industries Ltd.; Novartis AG etc.
Regional Analysis:
North America dominated the global depression treatment therapy market in 2016. The presence of a large number of pharmaceutical companies, availability of new generation antidepressants, and high healthcare expenditure are some factors attributed to its dominance. In addition, favorable government initiatives such as the launch of parity legislation for mental health disorders are also expected to drive growth over the forecast period.
Asia Pacific is estimated to be fastest growing region during the forecast period owing to increasing awareness about mental health disorders and their effective treatments coupled with rising disposable income levels in emerging countries such as China & India. Moreover, economic development has led to an increase in consumer spending on various products which will have a positive impact on regional growth over next few years.
Growth Factors:
- Increasing awareness about depression and its treatment options among people.
- Growing number of depression cases due to changing lifestyle, stress, and other factors.
- Rising demand for effective and affordable depression treatment therapies.
- Technological advancements in the field of depression treatment therapies.
Scope Of The Report
Report Attributes
Report Details
Report Title
Depression Treatment Therapy Market Research Report
By Type
Drugs, Treatment device
By Application
Seasonal affective disorder (SAD), Major depression, Dysthymia disorder, Postpartum depression, Atypical depression, Psychotic depression, Other
By Companies
Pfizer, Teva Pharmaceutical, Johnson and Johnson, Merck, Eli Lily, Novartis, Sanofi, AstraZeneca, Allergan, Mayo Clinic, Bristol-Myers Squibb, Takeda, Brainsway, Lundbeck, NeuroStar, Otsuka, VistaGen Therapeutics, Silver Oak Health, NeuroSigma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
206
Number of Tables & Figures
145
Customization Available
Yes, the report can be customized as per your need.
Global Depression Treatment Therapy Market Report Segments:
The global Depression Treatment Therapy market is segmented on the basis of:
Types
Drugs, Treatment device
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Seasonal affective disorder (SAD), Major depression, Dysthymia disorder, Postpartum depression, Atypical depression, Psychotic depression, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Teva Pharmaceutical
- Johnson and Johnson
- Merck
- Eli Lily
- Novartis
- Sanofi
- AstraZeneca
- Allergan
- Mayo Clinic
- Bristol-Myers Squibb
- Takeda
- Brainsway
- Lundbeck
- NeuroStar
- Otsuka
- VistaGen Therapeutics
- Silver Oak Health
- NeuroSigma
Highlights of The Depression Treatment Therapy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Drugs
- Treatment device
- By Application:
- Seasonal affective disorder (SAD)
- Major depression
- Dysthymia disorder
- Postpartum depression
- Atypical depression
- Psychotic depression
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Depression Treatment Therapy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Depression treatment therapy is a combination of medication and talk therapy. Medications used in depression treatment include antidepressants, mood stabilizers, and antipsychotics. Talk therapy can help people learn how to manage their emotions and improve their overall mental health.
Some of the major companies in the depression treatment therapy market are Pfizer, Teva Pharmaceutical, Johnson and Johnson, Merck, Eli Lily, Novartis, Sanofi, AstraZeneca, Allergan, Mayo Clinic, Bristol-Myers Squibb, Takeda, Brainsway, Lundbeck, NeuroStar, Otsuka, VistaGen Therapeutics, Silver Oak Health, NeuroSigma.
The depression treatment therapy market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Depression Treatment Therapy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Depression Treatment Therapy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Depression Treatment Therapy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Depression Treatment Therapy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Depression Treatment Therapy Market Size & Forecast, 2020-2028
4.5.1 Depression Treatment Therapy Market Size and Y-o-Y Growth
4.5.2 Depression Treatment Therapy Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Drugs
5.2.2 Treatment device
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Seasonal affective disorder (SAD)
6.2.2 Major depression
6.2.3 Dysthymia disorder
6.2.4 Postpartum depression
6.2.5 Atypical depression
6.2.6 Psychotic depression
6.2.7 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Depression Treatment Therapy Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Depression Treatment Therapy Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Drugs
9.6.2 Treatment device
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Seasonal affective disorder (SAD)
9.10.2 Major depression
9.10.3 Dysthymia disorder
9.10.4 Postpartum depression
9.10.5 Atypical depression
9.10.6 Psychotic depression
9.10.7 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Drugs
10.6.2 Treatment device
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Seasonal affective disorder (SAD)
10.10.2 Major depression
10.10.3 Dysthymia disorder
10.10.4 Postpartum depression
10.10.5 Atypical depression
10.10.6 Psychotic depression
10.10.7 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Drugs
11.6.2 Treatment device
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Seasonal affective disorder (SAD)
11.10.2 Major depression
11.10.3 Dysthymia disorder
11.10.4 Postpartum depression
11.10.5 Atypical depression
11.10.6 Psychotic depression
11.10.7 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Drugs
12.6.2 Treatment device
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Seasonal affective disorder (SAD)
12.10.2 Major depression
12.10.3 Dysthymia disorder
12.10.4 Postpartum depression
12.10.5 Atypical depression
12.10.6 Psychotic depression
12.10.7 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Drugs
13.6.2 Treatment device
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Seasonal affective disorder (SAD)
13.10.2 Major depression
13.10.3 Dysthymia disorder
13.10.4 Postpartum depression
13.10.5 Atypical depression
13.10.6 Psychotic depression
13.10.7 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Depression Treatment Therapy Market: Competitive Dashboard
14.2 Global Depression Treatment Therapy Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Teva Pharmaceutical
14.3.3 Johnson and Johnson
14.3.4 Merck
14.3.5 Eli Lily
14.3.6 Novartis
14.3.7 Sanofi
14.3.8 AstraZeneca
14.3.9 Allergan
14.3.10 Mayo Clinic
14.3.11 Bristol-Myers Squibb
14.3.12 Takeda
14.3.13 Brainsway
14.3.14 Lundbeck
14.3.15 NeuroStar
14.3.16 Otsuka
14.3.17 VistaGen Therapeutics
14.3.18 Silver Oak Health
14.3.19 NeuroSigma
